Omotola Olasupo and Colleagues Present Comparative Safety of Hemophilia Therapies in Canada
RPTH Journal shared on LinkedIn:
”Comparative safety of hemophilia therapies in Canada
Real-world comparative safety data for hemophilia therapies remain limited.
This study leverages national registry data to better understand adverse drug reactions across commonly used treatments using Canadian registry data over 5 years
- Allergic reactions were the most frequently reported adverse drug reactions
- A higher number of reported events was observed with emicizumab, although novelty bias cannot be excluded
- No inhibitor development was reported with emicizumab or bypassing agents
These findings provide important real-world insights into the relative safety of therapies used in hemophilia A and B, while highlighting the need for continued pharmacovigilance as treatment landscapes evolve.”
Read the full article here.
Article: Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study
Authors: Omotola Olasupo, Emma Iserman, Arun Keepanasseril, Quazi Ibrahim, Zainab Salim Ali Al-Housni, Federico Germini, Jean-Eric Tarride, Lawrence Mbuagbaw, Shannon Jackson, Ingrid Blydt-Hansen, Michelle Bech, Celina Woo, Mark Belletrutti, Alfonso Iorio, Davide Matino: the Association of Hemophilia Clinic Directors of Canada (AHCDC)
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?